- Regeneron, Bayer commence phase-3 trial for diabetic macular edema treatment
- GSK announces divestment of OTC brands
- Adherence among chronic disease patients can lead to big savings
- PhRMA: Nearly 300 preventive medicines for heart disease, stroke in development
- Moving PSE to Rx-only in Mo. lacks fiscal sense
TARRYTOWN, N.Y. — Bayer HealthCare and Regeneron Pharmaceuticals have started a late-stage clinical trial in China to evaluate a drug for eye disorders, the companies said Monday.
The drug makers announced the start of the phase-3 "SIGHT" trial of Eylea (aflibercept) injection for the treatment of the neovascular form of age-related macular degeneration, also known as wet AMD. The companies said the trial, which will include about 300 patients, will be the largest retinal trial conducted in China.
The U.S. Food and Drug Administration approved Eylea for wet AMD on Nov. 21.